IPCI's pending catalysts arriving and how much value that unlocks over these next 2 years are all that matters right youngprof88:)
The real players amongst us are all very well versed in all that's occurred here over the past 2 and a half years of the FDA's ongoing ANDA boondoggle/backlogged approval pipeline front...to the point that the over-whelming majority of longs could care less about the ANDA's anymore.
In fact the only 2 ANDA's I'm even expecting the FDA to move on this year still, are the additional FocalinXR strengths and SeroquelXR sometime this fall. Any other ANDA approvals or ANDA licensing deals that arrive this year will be taken as a pleasant surprise.
The number 1 catalyst in play right now from my perspective is the pending Rexista NDA submission on the heels of their human abuse and liability studies as you know...and quite frankly is the only thing that's relevant to me right now in how I determine this stocks future value as the next Rexista steps commence.
Rexista I with npodds, Rexista II with PODRAS and Regabatin over these next 20 to 24 months will transform this stock forever and the only thing these days will be looked back on as is the last available golden loading zone glty!
News 
Market Data 
Discover 
AI
